Table 2.
Primary prevention trials with atorvastatin
| Study | Population | Baseline mean LDL-C, mg/dL | N | Age range (mean ), y | No. in elderly subgroup (%); Age cutoff, y | Intervention | Median follow-up, y | Clinical end-point | RRR, %; (p) | ARR, % | NNT, % |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Older patients | Younger patients | |||||||||||
| CARDS, Elderly | Type 2 DM | 118 | 2838a | 65–75 | 1129 (40);a ≥65 | Atorvastatin 10 mg vs placebo | 3.9b | All-cause mortality | 22 (0.245) | 1.8 | 56 | 71 |
| First major CV event | 38 (0.017) | 3.9 | 21 | 33 | ||||||||
| Stroke | 49 (0.051) | 2 | 50 | 111 | ||||||||
| ASCOT-LLA | HTN | 131 | 10,305 | 40–79 (63) | 6570 (64) | Atorvastatin 10 mg vs placebo | 3.3b | CHD death and nonfatal MI | 36c (0.0027) | 1.2c | 83c | 125 |
a
Data from parent study, includes subjects < and ≥65 years.
b
Median.
c
Data from elderly subgroup.
Abbreviations: LDL-C, low-density lipoprotein cholesterol; RRR, relative risk reduction; ARR, absolute risk reduction; NNT, number needed to treat; CHD, coronary heart disease; MI, myocardial infarction; DM, diabetes mellitus; HTN, hypertension; CARDS, Collaborative Atorvastatin Diabetes Study; ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm.